Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1997-06-23
2000-04-04
Carlson, Karen Cochrane
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 44, 530350, A61K 3700, A61K 3170, A01N 4304, C07K 1400
Patent
active
060461659
ABSTRACT:
The invention provides compositions and methods of identifying and testing TGF-.beta. pathway agonists and antagonists, and in particular compositions comprising Mothers against DPP (MAD) proteins and related Smad polypeptides which exhibit sequence-specific DNA-binding activity. The invention also provides a novel DNA sequence (SEQ ID NO:19); (SEQ ID NO:20); (SEQ ID NO:21) that is bound with high affinity by Drosophila MAD protein. This protein is useful for identifying compounds that will enhance or interfere with MAD protein-DNA binding.
REFERENCES:
patent: 4683195 (1987-07-01), Mullis et al.
patent: 4683202 (1987-07-01), Mullis
patent: 5556752 (1996-09-01), Lockhart et al.
patent: 5652096 (1997-07-01), Cimino
J. Massague,"TGF.beta.Signaling: Receptors, Transducers, and Mad Proteins," Cell 85:947-950 (1996).
Attisano et al., "Activation of the signaling by the activin receptor complex." Mol. Cell. Biol. 16:, 1066-1073 (1996).
V. Wiersdorff et al., "Mad acts downstream Of Dpp receptors, revealing a differential requirement for dpp signaling in initiation and propagation of morphogenesis in the Drosophila Eye," Development 122:2153-2162 (1996).
R. Weiser et al., "GS domain mutations that constitutively activate TGF.beta.R-1, the downstream signaling component in the TGF-.beta. receptor complex," EMBO J., 14:2199-2208 (1995).
F. Liu et al., "A Human Mad Protein Acting As a BMP-regulated Transcriptional Activator," Nature 381:620-623 (1996).
R. Derynck and Y. Zhang, "Intracellular Signalling: The Mad Way To Do It," Curr. Biol. 6:1226-1229 (1996).
Raftery et al., "Genetic Screens to Identify Elements of the decapentaplegic Signaling Pathway In Drosophila," Genetics 139:241-254 (1995).
Savage et al., "Caenorhabditis elegans genes sma-2, sma-3 and sma-4 define a conserved family of transforming growth factor .beta. Pathway Components," Proc. Natl. Acad. Sci . USA 93:790-794 (1996).
Lagna et al., "Partnertship between DPC4 and SMAD proteins in TGF-.beta. singnaling pathways," Nature 383:832-836 (1996);
Hoodless et al., "MADRI, a MAD-Related Protein That Functions In BMP2 Signaling Pathways," Cell 85:489-500 (1996).
Baker and Harland, "A novel mesoderm inducer, Madr2, functions in the activin signal transduction pathway," Genes Dev. 10:1880-1889 (1996).
Vrana et al.,"Expression of Tissue Factor in Tumor Stroma Correlates with Progression to invasive Human Breast Cancer: Paracrine Regulation by Carcinoma Cell-derived Members of the Transforming Growth Factor .beta. Family," Cancer Res. 56(21):5063-5070 (1996).
Mercier et al., "Calcitriol and Lexicalcitol (KH1060) Inhibit the Growth of Human Breast Adenocarcinoma Cells by Enhancing Transforming Growth Factor-.beta. Production," Biochem. Pharmacol. 52(3):505-510 (1996).
Dannecker et al., "Induction of TGF-beta by an antiprogestin in the human breast cancer cell line T-47D," Ann. of Onco. 7(4):391-395 (1996).
Kong, "Elevated Plasma Transforming Growth Factor-.beta..sub.1 Levels in Breast Cancer Patients Decrease After Surgical Removal of the Tumor," Ann. Surg. 222(2):155-162 (1995).
Robson et al., "Transforming growth factor .beta.1 expression in human colorectal tumours: an independent prognostic marker in a subgroup of poor prognosis patients," Brit. J. Cancer. 74(5):753-758 (1996).
Tsushima et al., "High Levels of Transforming Growth Factor .beta.1 in Patients With Colorectal Cancer: Assocation With Disease Progression," Gastroenterol. 110(2):375-382 (1996).
Akiyama "Transforming Growth Factor .beta. Type II Receptor Gene Mutations in Adenomas From Hereditary Nonpolyposis Colorectal Cancer," Gastroenterol. 112(1):33-39 (1997).
Souza et al., "A Transforming Growth Factor .beta.1 Receptor Type II Mutation in Ulcerative Colitis-Associated Neoplasms," Gastroenterol. 112(1):40-45 (1997).
Togo et al,, "A Transforming Growth Factor .beta. Type II Receptor Gene Mutation Common in Sporadic Cecum Cancer with Microsatellite Instability," Cancer Res. 56(24):5620-5623 (1996).
Fakhrai et al., "Eradication of established intracranial rat gliomas by transforming growth factor .beta. antisense gene therapy," Proc. of the Natl. Acad. of Sci. USA 93(7):2909-2914 (1996).
Weller and Fontana, "The failure of current immunotherapy for malignant glioma. Tumor-derived TGF-.beta., T-cell apoptosis, and the immune privilege of the brain," Brain Res. Rev. 21(2):128-151 (1995).
Perry et al., "Transforming Growth Factors Beta as a Clinical Biomarker for Prostate Cancer," Urology 49(1):151-155 (1997).
Roberson et al., "Fenretinide: Induction of Apoptosis and Endogenous Transforming Growth Factor .beta. in PC-3 Prostate Cancer Cells," Cell. Growth and Diff. 8(1):101-111 (1997).
Junker et al., "Transforming Growth Factors Beta 1 is Significantly Elevated in Plasma of Patients Suffering from Renal Cell Carcinoma," Cytokine 8(10):794-798 (1996).
M. R. Keeton et al.. "Identification of the regulatory sequences in the type 1 Plasinogen Activator Inhibitor Gene Rresponsive to Transforming Growth Factor .beta.," J. Biol. Chem. 34: 23048-23052.
Wrana et al., "TGF-.beta. signals through a heterotrimeric protein kinase receptor complex," Cell 71: 1003-1014 (1992).
R. P. deGroot and W. Kruijer, "Transcriptional activation by TGF.beta.1 mediated by the dyad symmetry element (DSE) and the TPA responsive element (TRE)," Biochem. Biophys. Res. Commun. 168:1074-1081(1990).
Chen et al., "A transcriptional partner for MAD proteins in TGF-.beta. signalling," Nature 383:691-695 (1996).
Li et al., "Transforming Growth Factor .beta.Activates the promoter of Cyclin-dependent kinase inhibitor p15.sup.INK4B through an Sp1 consensus site," J.Biol.Chem. 270:26750-26753, (1995).
R. Derynck et al., "Nomenclature: Vertebrate Mediators of TGF.beta. Family Singnals," Cell, 87:173 (1996).
J. Sekelsky et al., "Genetic Characterization And Cloning Of Mothers Against Dpp, A Gene Required For Decapentaplegic Function In Drosophila Melanogaster," Genetics 139:1347-1358 (1995).
Marmur and Lane, "Strand Separation and Specific Recombination in Deoxyribonucleic Acids: Biological Studies," Proc. Natl. Acad. Sci. USA 46:453-461 (1960).
Doty et al., "Strand Separation and Specific Recombination in Deoxyribonucleic Acids: Physical Chemical Studies," Proc. Natl. Acad. Sci. USA 46:461-476 (1960).
Wallace et al.,"Application of Synthetic Oligonucleotides to the Diagnosis of Human Genetic Diseases," Biochimie 67:755-762 (1985).
Studencki and Wallace," Allele-Specific Hybridization Using Oligonucleotidee Probes of Very High Specific Acitvity: Discriminaation of the Human .beta..sup.A -and .beta..sup.A -Globin Genes," DNA 3: 7-15 (1984).
Studencki et al., "Discrimination Among the Human .beta..sup.A, .beta..sup.S, and .beta..sup.C -Globin Genes Using Allele-Specific Oligonucleotide HydridizationProbes," Human Genetics 37:42-51 (1995).
Smith and Waterman,"Comprison of Biosequences," Adv. Appl. Math. 2: 482-489 (1981).
Needleman and Wunsch, "A General Method Applicable too the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol. 48:443-453 (1970).
Pearson and Lipman, "Improved Tools for Biolgical Sequence Comparison," Proc. Natl. Acad. Sci. (U.S.A.)85: 2444-2448 (1988).
Y. Zhang edt al., "Receptor-associated Mad Homologues Synergize As Effectors Of The TGF-beta Response," Nature 383:168-172 (1996).
Bowie et al., "A Method to Identify Protein Sequences The Fold in to a Known Three-Dimensional Structure," Science 253:164-170 (1991).
Thorton et al., "Prediction of progress at last," Nature 354:105-106 (1991).
Fauchere, J., "Elements for the Rational Design of Peptide Drugs," Adv. Drug. Res. 15:29-67 (1986).
Veber and Freidinger, "The design of metabolically-stable peptide analogs," TINS p.392-396 (1985).
Evans et al., "Design of Nonpeptidal Ligands for a Peptide Receptor: Cholecystokinin Antagonists," J. Med. Chem 30:1229-1239 (1987).
Rizo & Gierasch, "Constrained Peptides: Models of Bioactive Peptides and Protein Substructures," Ann. Rev. Biochem. 61:387-418 (1992).
Cui et al., "TGF.beta.1 Inhibits the Formation of Bening Skin Tumors, but Enhances Progression to Invasive Spindle Carcinom
Johnson Kirby
Kim Jaeseob
Laughon Allen
Carlson Karen Cochrane
Ophidian Pharmaceuticals Inc.
LandOfFree
Compositions and methods for identifying and testing TGF-.beta. does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for identifying and testing TGF-.beta. , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for identifying and testing TGF-.beta. will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365036